News

Milestones struck as Prescient due to emerge from ‘stealth mode’ on new tech

March 2, 2022

Milestones struck as Prescient due to emerge from ‘stealth mode’ on new tech

Cancer-fighting biotech company Prescient Therapeutics has continued to hit its clinical and development milestones in the first half of the financial year, its reports show.

Cancer-fighting biotech company Prescient Therapeutics has continued to hit its clinical and development milestones in the first half of the financial year, its reports show.

The company – which is developing two novel cancer treatments (PTX-100 and PTX-200) and a next-generation cell therapy platform – met several development targets during the six months ending December 2021.

These included progressing human trials for PTX-100 to higher dosages after earlier research indicated the relatively safe nature of treatment, and seeking a new cohort to test PTX-200 following the completion of Phase 1b studies.

The company also made “significant progress” in three preclinical trials of its next-generation CAR-T cell therapy platform, OmniCAR.

CAR-T is a form of cell therapy that reprograms a patient’s immune system to identify and attack cancer cells. 

OmniCAR was developed using technology licensed from the University of Pennsylvania and Oxford University – both pioneers in CAR-T – and is intended to make CAR-T safer and more flexible.

Prescient undertook testing of its OmniCAR platform in three types of cancer: acute myeloid leukaemia, HER2+ solid tumours (including ovarian, gastric and breast cancer) and glioblastoma multiforme (a type of brain cancer). 

“The results showed that OmniCAR-T cells begin antigen-directed killing of tumour cells in vitro as soon as they are armed,” Prescient said.

“The company also showed that OmniCAR-T cells could be re-armed and continue to kill tumour cells without loss of cytotoxicity, and that OmniCAR can be used to target multiple cancer antigens.”

Prescient Therapeutics noted it is also working on new technologies that it says will “complement, enhance and expand” the usefulness of existing CAR-T therapies.

This work is being undertaken in “stealth mode” for commercial purposes; however, the company said “significant progress” was made during the period.

Prescient Therapeutics CEO Steven Yatomi-Clarke will be hosting an investor briefing Thursday, 3rd March, at 1pm (AEDT). Click here to register.

Reach Markets have been engaged by PTX to assist with their investor communications.

Sources:


General Advice Warning

Any advice provided by Reach Markets including on its website and by its representatives is general advice only and does not consider your objectives, financial situation or needs, and you should consider whether it is appropriate for you. This might mean that you need to seek personal advice from a representative authorised to provide personal advice. If you are thinking about acquiring a financial product, you should consider our Financial Services Guide (FSG) including the Privacy Statement and any relevant Product Disclosure Statement or Prospectus (if one is available) to understand the features, risks and returns associated with the investment.

Please click here to read our full warning.

Morning Market Report

A technical view of the Australian and key international markets

Leave a comment